Trio of IgA Nephropathy Drugs Proves Mettle in Interim Analyses
(MedPage Today) -- DENVER -- Significant proteinuria reductions were reported in phase III interim analyses assessing two investigational IgA nephropathy agents and a third that was recently granted accelerated approval. First, in the RAINIER...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.